ArcherZyme
Pre-clinical- Indications
- Body odor, Acne
Company intelligence / Profile preview
ArrowBiome has demonstrated significant efficacy and selectivity with its lysin-based technology across multiple bacterial strains relevant to skin conditions such as acne and body odor. The approach allows for over 100 times lower doses of active ingredients compared to current products while maintaining a healthy microbiome balance and minimizing antibiotic resistance risk. Clinical validation and R&D are ongoing with initial focus on personal care applications.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ArrowBiome.